Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment
{{output}}
Most people with type 2 diabetes have metabolic dysfunction-associated steatotic liver disease (MASLD), yet fewer than 2% experience major adverse liver outcomes within 10 years. Because progression to end-stage liver disease is uncommon, identifying the small... ...
